Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapSuper Stock

REG - JPMorgan Sec.Plc Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Takeda Pharmaceutical Co Ltd





 




RNS Number : 0532H
JPMorgan Securities Plc
12 November 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical Company Limited

(c) Name of the party to the offer with which exempt principal trader is connected:

Joint Financial Adviser to Takeda Pharmaceutical Company Limited

(d) Date dealing undertaken:

09 November 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

     If it is a cash offer or possible cash offer, state "N/A"

Yes, Shire plc

 

 

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

(JPY)

Lowest price per unit paid/received

(JPY)

Common Stock

Purchases

 

Sales

287,137

 

290,698

4554.9700

 

4554.9700

4497.0000

 

4497.0000

 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

Common Stock

Equity Swaps

Long

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short

139,300

 700

 900

 139,300

 100

 500

 100

 5,000

 100

 3,500

 200

 41,300

 9,000

 100

 19,200

 100

 

 400

 300

 1,100

 139,300

 100

 3,100

 100

 600

 3,600

 65,500

 111,000

 3,400

 28,300

 2,500

 100

39.8509 USD

 4,497.0000 JPY

 4,497.3333 JPY

 4,509.0000 JPY

 4,513.4500 JPY

 4,520.8000 JPY

 4,524.7511 JPY

 4,525.7000 JPY

 4,536.0000 JPY

 4,536.9429 JPY

 4,537.0000 JPY

 4,537.0145 JPY

 4,538.3152 JPY

 4,546.0000 JPY

 4,549.8177 JPY

 4,550.5449 JPY

 

 4,497.0000 JPY

 4,497.3822 JPY

 4,504.7933 JPY

 4,509.0000 JPY

 4,513.4513 JPY

 4,523.7742 JPY

 4,525.0000 JPY

 4,525.5656 JPY

 4,537.2569 JPY

 4,540.1535 JPY

 4,540.6856 JPY

 4,543.2059 JPY

 4,547.6007 JPY

 4,550.9200 JPY

 4,551.0000 JPY

 

(c)        Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

 

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 









 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 





 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)


 

 



 

3.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

12 November 2018

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERLLFFILDLFLIT

Recent news on Takeda Pharmaceutical Co

See all news